Hellström-Lindberg E - Search Results

1

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.

Scharenberg C, Giai V, Pellagatti A, Saft L, Dimitriou M, Jansson M, Jädersten M, Grandien A, Douagi I, Neuberg DS, LeBlanc K, Boultwood J, Karimi M, Jacobsen SE, Woll PS, Hellström-Lindberg E. Scharenberg C, et al. Haematologica. 2017 Mar;102(3):498-508. doi: 10.3324/haematol.2016.152025. Epub 2016 Nov 24. Haematologica. 2017. PMID: 27884971 Free PMC article.

2

Sixth International Symposium on Myelodysplastic Syndromes, Stockholm, June 14-17, 2001.

Hellström-Lindberg E. Hellström-Lindberg E. Int J Hematol. 2002 Feb;75(2):209-12. doi: 10.1007/BF02982031. Int J Hematol. 2002. PMID: 11939272 No abstract available.

3

Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.

Nilsson L, Astrand-Grundström I, Anderson K, Arvidsson I, Hokland P, Bryder D, Kjeldsen L, Johansson B, Hellström-Lindberg E, Hast R, Jacobsen SE. Nilsson L, et al. Blood. 2002 Jul 1;100(1):259-67. doi: 10.1182/blood-2001-12-0188. Blood. 2002. PMID: 12070035 Free article.

4

Approach to anemia associated with myelodysplastic syndromes.

Hellström-Lindberg E. Hellström-Lindberg E. Curr Hematol Rep. 2003 Mar;2(2):122-9. Curr Hematol Rep. 2003. PMID: 12901143 Review.

5

Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.

Ljung T, Bäck R, Hellström-Lindberg E. Ljung T, et al. Haematologica. 2004 Dec;89(12):1446-53. Haematologica. 2004. PMID: 15590394

6

Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.

Tehranchi R, Invernizzi R, Grandien A, Zhivotovsky B, Fadeel B, Forsblom AM, Travaglino E, Samuelsson J, Hast R, Nilsson L, Cazzola M, Wibom R, Hellström-Lindberg E. Tehranchi R, et al. Blood. 2005 Jul 1;106(1):247-53. doi: 10.1182/blood-2004-12-4649. Epub 2005 Mar 8. Blood. 2005. PMID: 15755901 Free article.

7

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E. Jädersten M, et al. Blood. 2005 Aug 1;106(3):803-11. doi: 10.1182/blood-2004-10-3872. Epub 2005 Apr 19. Blood. 2005. PMID: 15840690 Free article. Clinical Trial.

8

Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.

Tehranchi R, Fadeel B, Schmidt-Mende J, Forsblom AM, Emanuelsson E, Jadersten M, Christensson B, Hast R, Howe RB, Samuelsson J, Zhivotovsky B, Hellström-Lindberg E. Tehranchi R, et al. Clin Cancer Res. 2005 Sep 1;11(17):6291-9. doi: 10.1158/1078-0432.CCR-04-1850. Clin Cancer Res. 2005. PMID: 16144933

9

Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.

Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L, Porwit-MacDonald A, Sjoo M, Tangen JM, Uggla B, Oberg G, Hellstrom-Lindberg E. Broliden PA, et al. Haematologica. 2006 May;91(5):667-70. Haematologica. 2006. PMID: 16670072 Clinical Trial.

10

Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.

Goss TF, Szende A, Schaefer C, Totten PJ, Knight R, Jädersten M, Hellström-Lindberg E, List AF. Goss TF, et al. Cancer Control. 2006 Dec;13 Suppl:17-25. doi: 10.1177/107327480601304s04. Cancer Control. 2006. PMID: 17242663 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

285 results

Search Page

Filters